Multiple sclerosis: Remyelination of nascent lesions: Remyelination of nascent lesions
The DOI matches its Crossref record; 45 of the 46 references it cites were found in a registry or an index.
Abstract
The relationship between plaque pathology and disease duration was examined in 15 patients with multiple sclerosis who died early in the course of their illness. Myelin-stained sections revealed that most plaques examined in patients who died during the first month of their illness showed evidence of ongoing myelin destruction accompanied by a loss of oligodendrocytes. Plaques containing large numbers of oligodendrocytes were not observed in these patients, but were relatively common in patients who died more than 1 month after clinical onset. Remyelination affecting more than 10% of the plaque area was observed in 3 of 82 plaques in 5 patients who died within 10 weeks of clinical onset, in 38 of 105 plaques in 5 patients who died 3 to 10 months after clinical onset, and in 19 of 92 plaques in 5 patients who died 18 months or longer after clinical onset. The study provides new evidence that both oligodendrocytes and myelin are destroyed in new lesions, that this activity ceases completely in many lesions within a few weeks, and that remyelination frequently ensues following repopulation of the plaque by oligodendrocytes. The findings suggest that new lesions normally remyelinate unless interrupted by recurrent activity and that remyelinated shadow plaques are the outcome of a single previous episode of focal demyelination.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For cortical grey matter, this now indicates that oligodendrocyte recruitment and remyelination is an early phenomenon in MS lesion formation that occurs in the immediate post-phagocytic phase when foam cells are still abundant in the demyelinated lesions.56-60”
From BCAS1-positive oligodendrocytes enable efficient cortical remyelination in multiple sclerosis (2025) · cites this paper as [57]
In the citing paper
“However, despite remyelination being very efficient at the early stages of the disease, this process gradually fails over time [115,116].”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [115]
Citations
Cites
Handbook of clinical neurology
(1986) · Journal of Neuroimmunology · doi:10.1016/0165-5728(86)90030-5 · Cited by 1,849
Lantos, P. (1985) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.48.5.496 · Cited by 1,152
Walton, J. N. (1976) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(76)90157-x · Cited by 964
Payne, J. P. (1969) · British Journal of Anaesthesia · doi:10.1093/bja/41.4.356 · Cited by 600
Remyelination in multiple sclerosis
Prineas, J. W., & Connell, F. (1979) · Annals of Neurology · doi:10.1002/ana.410050105 · Cited by 454
Self-citationRemyelination in multiple sclerosis
Piaton, G., Williams, A., Seilhean, D., & Lubetzki, C. (2009) · Progress in Brain Research · doi:10.1016/s0079-6123(09)17530-1 · Cited by 441
ULTRASTRUCTURAL STUDY OF REMYELINATION IN AN EXPERIMENTAL LESION IN ADULT CAT SPINAL CORD
Bunge, M. B., Bunge, R. P., & Ris, H. (1961) · The Journal of Cell Biology · doi:10.1083/jcb.10.1.67 · Cited by 396
Proliferating bipotential glial progenitor cells in adult rat optic nerve
ffrench-Constant, C., & Raff, M. C. (1986) · Nature · doi:10.1038/319499a0 · Cited by 385
Comparative Neuropathology of Chronic Experimental Allergic Encephalomyelitis and Multiple Sclerosis
Lassmann, H. (1983) · Schriftenreihe Neurologie / Neurology Series · doi:10.1007/978-3-642-45558-2 · Cited by 296
Pathology of the Nervous System
Krigman, M. R. (1969) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1969.03160150057026 · Cited by 286
Research works printed but not linked: 3
- Schlesinger H, 1909, Zur Frage der akuten multiplen Sklerose und der Enzephalomyelitis disseminata im Kindesalter, Arch Neurol Inst, Wien, 17, 410
- Greenfield JG, 1958, Neuropathology, 441
- Jacob H, 1969, Tissue process in multiple sclerosis and parainfectious and post‐vaccinal encephalomyelitis, Int Arch Allergy Appl Immunol, 36, 22
Cited by
Items 301–400 of 571
Gene therapy in the treatment of autoimmune disease
Mathisen, P. M., & Tuohy, V. K. (1998) · Immunology Today · doi:10.1016/s0167-5699(97)01214-0 · Cited by 31
Noseworthy, J. H., O’Brien, P. C., van Engelen, B. G. M., & Rodriguez, M. (1994) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.57.suppl.11 · Cited by 31
Choi, E. H., Xu, Y., Medynets, M., Monaco, M. C., Major, E. O., Nath, A., & Wang, T. (2018) · Glia · doi:10.1002/glia.23501 · Cited by 31
Walczak, P., & Janowski, M. (2019) · Neuropsychiatry · doi:10.4172/neuropsychiatry.1000565 · Cited by 32
Wilczak, N., Chesik, D., Hoekstra, D., & Keyser, J. D. (2008) · Neurochemistry International · doi:10.1016/j.neuint.2008.03.004 · Cited by 30
“Remyelination of multiple sclerosis (MS) plaques, although often limited in its extent, can be observed during the early stages of the disease, but largely fails as the disease progresses (Prineas et al., 1993; Raine and Wu, 1993).”
Expression of Golli proteins in adult human brain and multiple sclerosis lesions
Filipovic, R., Rakić, S., & Zečević, N. (2002) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(02)00070-x · Cited by 33
Immunoglobulin-mediated CNS repair☆☆☆★
Warrington, A. E., Bieber, A. J., Ćirić, B., Keulen, V. P. V., Pease, L. R., Mitsunaga, Y., Soldán, M. M. P., & Rodriguez, M. (2001) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2001.118301 · Cited by 30
Are there indicators of remyelination in blood or CSF of multiple sclerosis patients?
Massaro, A. R. (1998) · Multiple Sclerosis Journal · doi:10.1177/135245859800400326 · Cited by 31
Multiple sclerosis: The resolving lesion revealed
Raine, C. S. (2016) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2016.05.021 · Cited by 29
“Although resolving lesions per se in MS have been largely overlooked, one study by Prineas et al. (1993a) on CNS remyelination in nascent MS lesions did mention them briefly.”
BackgroundZumkeller, W. (1997) · European Journal of Paediatric Neurology · doi:10.1016/s1090-3798(97)80039-6 · Cited by 31
Remyelination of the central nervous system
Compston, A. (1996) · Multiple Sclerosis Journal · doi:10.1177/135245859600100622 · Cited by 32
Whitaker, J. N., Williams, P. H., Layton, B. A., McFarland, H. F., Stone, L. A., Smith, M. E., Kachelhofer, R. D., Bradley, E. L., Burgard, S. L., Zhao, G., et al. (1994) · Annals of Neurology · doi:10.1002/ana.410350511 · Cited by 29
Hallmarks of spinal cord pathology in multiple sclerosis
Kreiter, D., Postma, A. A., Hupperts, R., & Gerlach, O. H. H. (2023) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2023.122846 · Cited by 43
“The latter are only seen in spinal cord lesions [38,39].”
Markovic‐Plese, S., Singh, A. K., & Singh, I. (2008) · Future Neurology · doi:10.2217/14796708.3.2.153 · Cited by 29
Miller, D. J., & Rodriguez, M. (1995) · Microscopy Research and Technique · doi:10.1002/jemt.1070320306 · Cited by 28
The Complement System in Central Nervous System Diseases
Rus, H., & Niculescu, F. I. (2001) · Immunologic Research · doi:10.1385/ir:24:1:79 · Cited by 28
The neuroimmunology of multiple sclerosis
Coyle, P. K. (1996) · Advances in Neuroimmunology · doi:10.1016/0960-5428(96)00013-7 · Cited by 34
Treatment and Relapse Prevention of Typical and Atypical Optic Neuritis
Saitakis, G., & Chwalisz, B. K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179769 · Cited by 36
Armstrong, R. C. (2007) · Future Neurology · doi:10.2217/14796708.2.6.689 · Cited by 27
Toh, C., Wei, K., Ng, S.-H., Wan, Y., Castillo, M., & Lin, C. (2011) · American Journal of Neuroradiology · doi:10.3174/ajnr.a2871 · Cited by 28
Abramowski, P., Krasemann, S., Ernst, T., Lange, C., Ittrich, H., Schweizer, M., Zander, A. R., Martinꝉ, R., & Fehse, B. (2016) · Stem Cells and Development · doi:10.1089/scd.2016.0020 · Cited by 31
McFarland, H. F., & Reingold, S. C. (2005) · Multiple Sclerosis Journal · doi:10.1191/1352458505ms1231oa · Cited by 31
Kelland, E. E., Gilmore, W., Weiner, L. P., & Lund, B. T. (2011) · Glia · doi:10.1002/glia.21230 · Cited by 31
“Early in the course of MS, both neural stem cells (NSC) and oligodendrocyte progenitor cells (OPC) appear to be recruited to the lesion sites, where some remyelination occurs (Chang et al., 2000; Prineas et al., 1993; Snethen et al., 2008; Wolswijk, 2002).”
BackgroundPurification of immunologically active recombinant 21.5 kDa isoform of human myelin basic protein
Nye, S. H., Pelfrey, C. M., Burkwit, J. J., Voskuhl, R. R., Lenardo, M. J., & Mueller, J. P. (1995) · Molecular Immunology · doi:10.1016/0161-5890(95)00066-6 · Cited by 29
Zhang, L., Yu, W., Schroedter, I., Kong, J., & Vrontakis, M. E. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033901 · Cited by 29
Felts, P. A., & Smith, K. J. (1996) · Neuroscience · doi:10.1016/0306-4522(96)00282-5 · Cited by 29
Lassmann, H. (2005) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2005.03.007 · Cited by 25
CONTRAST ENHANCEMENT AND THE ACUTE LESION IN MULTIPLE SCLEROSIS
Rovaris, M., & Filippi, M. (2000) · Neuroimaging Clinics of North America · doi:10.1016/s1052-5149(25)00669-0 · Cited by 26
Glial precursor cell transplantation therapy for neurotrauma and multiple sclerosis
Kulbatski, I., Mothe, A. J., Parr, A. M., Kim, H. S., Kang, C. E., Bozkurt, G., & Tator, C. H. (2008) · Progress in Histochemistry and Cytochemistry · doi:10.1016/j.proghi.2008.04.001 · Cited by 29
Paintlia, A. S., Paintlia, M. K., Hollis, B. W., Singh, A. K., & Singh, I. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.05.028 · Cited by 25
Pérez-Bouza, A., Glaser, T., & Brüstle, O. (2005) · Brain Pathology · doi:10.1111/j.1750-3639.2005.tb00522.x · Cited by 28
VENTILATORY DYSFUNCTION IN MULTIPLE SCLEROSIS
Carter, J. L., & Noseworthy, J. H. (1994) · Clinics in Chest Medicine · doi:10.1016/s0272-5231(21)00962-x · Cited by 26
Filippi, M., Rocca, M. A., Horsfield, M. A., & Comı, G. (1998) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(98)00126-9 · Cited by 26
Ciapă, M. A., Șalaru, D. L., Stătescu, C., Sascău, R. A., & Bogdănici, C. M. (2022) · Current Issues in Molecular Biology · doi:10.3390/cimb44090272 · Cited by 37
“Endogenous remyelination after ON appears to be most prominent in optic nerve lesions that develop early in the course of MS, and when significant remyelination occurs, it usually becomes morphologically apparent at least 1 month after the initial insult, a time interval that corresponds to clinical recovery after iso…”
BackgroundWang, C.-J., Qu, C., Zhang, J., Fu, P., Guo, S., & Tang, R. (2014) · The Anatomical Record · doi:10.1002/ar.22988 · Cited by 24
“In addition, the newly formed myelin sheaths may have abnormal structures, such as shorter intermodal length and thin myelin sheath (Prineas and Connell, 1979; Prineas et al., 1993).”
BackgroundCellular Damage and Repair in Multiple Sclerosis
Lassmann, H. (2004) · Elsevier eBooks · doi:10.1016/b978-012439510-7/50084-x · Cited by 28
Does inflammation stimulate remyelination?
Hohlfeld, R. (2007) · Journal of Neurology · doi:10.1007/s00415-007-1009-6 · Cited by 25
Lassmann, H., & Vass, K. (1995) · Springer Seminars in Immunopathology · doi:10.1007/bf00194101 · Cited by 39
Lohrberg, M., Winkler, A., Franz, J., van der Meer, F., Ruhwedel, T., Sirmpilatze, N., Dadarwal, R., Löber-Handwerker, R., Esser, D. S., Wiegand, K., et al. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-01105-2 · Cited by 26
Magnetisation transfer imaging in multiple sclerosis.
Filippi, M., & Rovaris, M. (2000) · PubMed · Cited by 28
A Novel Microtubule‐Associated Protein‐2 Expressed in Oligodendrocytes in Multiple Sclerosis Lesions
Shafit‐Zagardo, B., Kress, Y., Zhao, M. L., & Lee, S. C. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0732531.x · Cited by 25
“J. Neurochem., Vol. 73, No. 6, 1999 Demonstration of MAP-21131 regenerating oligodendrocytes in lesions of MS brains confirms the numerous previously documented phenomena that adult human brain possesses the ability to repair myelin damage (Prineas et al., 1993; Yao et al., 1995; Raine, 1997a,b).”
BackgroundAutologous mesenchymal bone marrow stem cells: Practical considerations
Scolding, N. J., Marks, D. I., & Rice, C. M. (2007) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2007.08.009 · Cited by 26
Oligodendrocyte Physiology and Pathology Function
Kipp, M. (2020) · Cells · doi:10.3390/cells9092078 · Cited by 26
Remyelinating and neuroprotective treatments in multiple sclerosis
Stangel, M. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.4.331 · Cited by 22
Dąbrowski, W., Kwiecień, J. M., Rola, R., Kłapeć, M., Stanisz, G. J., Kotlińska-Hasiec, E., Oakden, W., Janik, R., Coote, M., Frey, B. N., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0142598 · Cited by 22
Multiple sclerosis: a unique immunopathological syndrome of the central nervous system
Hunter, S. F., & Rodriguez, M. (1995) · Springer Seminars in Immunopathology · doi:10.1007/bf00194102 · Cited by 22
de Jong, C. G. H. M., Stancic, M., Pinxterhuis, T. H., van Horssen, J., van Dam, A., Gabius, H., & Baron, W. (2018) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nly081 · Cited by 22
The Conduction Properties of Demyelinated and Remyelinated Axons
Smith, K. J., & Waxman, S. G. (2005) · Elsevier eBooks · doi:10.1016/b978-012738761-1/50007-9 · Cited by 22
Remyelination modulators in multiple sclerosis patients
Al-Temaimi, R. A., Abubaker, J. A., Al‐Khairi, I., & Alroughani, R. (2017) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2017.11.004 · Cited by 24
Re-Expression of a Developmentally Restricted Potassium Channel in Autoimmune Demyelination
Herrero-Herranz, E., Pardo, L. A., Bunt, G., Gold, R., Stühmer, W., & Linker, R. A. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2007.061241 · Cited by 27
Pender, M. P. (2000) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2000.tb124107.x · Cited by 23
Altmann, D. R., Button, T., Schmierer, K., Hunter, K., Tozer, D. J., Wheeler‐Kingshott, C. A. M. G., Coles, A. J., & Miller, D. H. (2013) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2013.09.007 · Cited by 20
Interferon β-1b directly modulates human neural stem/progenitor cell fate.
Arscott, W. T., Soltys, J., Knight, J., & Mao-Draayer, Y. (2011) · Brain Research · doi:10.1016/j.brainres.2011.07.037 · Cited by 22
Rinalduzzi, S. (2001) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.70.1.28 · Cited by 20
Laquinimod Supports Remyelination in Non-Supportive Environments
Nyamoya, S., Steinle, J., Chrzanowski, U., Kaye, J., Schmitz, C., Beyer, C., & Kipp, M. (2019) · Cells · doi:10.3390/cells8111363 · Cited by 20
Caba, B., Cafaro, A., Lombard, A., Arnold, D. L., Elliott, C., Liu, D., Jiang, X., Gafson, A., Fisher, E., Belachew, S. M., et al. (2022) · NeuroImage · doi:10.1016/j.neuroimage.2022.119787 · Cited by 20
Progression in multiple sclerosis is associated with low endogenous NCAM
Gnanapavan, S., Ho, P. P.-K., Heywood, W., Jackson, S., Grant, D., Rantell, K. R., Keir, G., Mills, K. A., Steinman, L., & Giovannoni, G. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12236 · Cited by 19
“Remyelination is a consistent feature in early lesions as evidenced by shadow plaques (Prineas et al. 1993).”
BackgroundFrom Stem Cells to Oligodendrocytes: Prospects for Brain Therapy
Chen, C. P., Kiel, M. E., Sadowski, D. H., & McKinnon, R. D. (2007) · Stem Cell Reviews and Reports · doi:10.1007/s12015-007-9006-9 · Cited by 19
Herpesviruses—a rationale for antiviral treatment in multiple sclerosis
Bergström, T. B. (1999) · Antiviral Research · doi:10.1016/s0166-3542(98)00067-9 · Cited by 20
“The progression of neurological deficits in MS often follows a relapsing–remitting course, where exacerbations are associated with expanding or new areas of demyelination in the CNS, and recovery with remyelination (Prineas et al., 1993).”
BackgroundChapter 28 Immune promotion of central nervous system remyelination
Rodriguez, M., & Miller, D. J. (1994) · Progress in brain research · doi:10.1016/s0079-6123(08)61148-6 · Cited by 19
Suppressive effects of TNF-α on myelin formationin vitro
Tsukamoto, T., Ishikawa, M., & Yamamoto, T. (1995) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1995.tb05847.x · Cited by 19
Landtblom, A., Sjöqvist, L., Söderfeldt, B. A., Nyland, H., & Thuomas, K.-Å. (1996) · Acta Radiologica · doi:10.1177/02841851960371p160 · Cited by 22
Zuroff, L. R., Farkhondeh, V., Bove, R. M., & Green, A. (2025) · Drugs · doi:10.1007/s40265-025-02212-x · Cited by 22
“Remyelination in the diseased state is incomplete [12–15].”
Copelman, C. A., Diemel, L. T., Gveric, D., Gregson, N. A., & Cuzner, M. L. (2001) · Journal of Neuroscience Research · doi:10.1002/jnr.10026 · Cited by 18
“Paradoxically macrophages, which are implicated in angiogenesis, gliogenesis, and modelling of the central nervous system (CNS) during development (Giulian et al., 1988), have also been associated with the microscopic hallmarks of remyelination in MS (Prineas et al., 1993).”
BackgroundRemyelination-Promoting Human IgMs: Developing a Therapeutic Reagent for Demyelinating Disease
Warrington, A. E., & Rodriguez, M. (2007) · Current topics in microbiology and immunology · doi:10.1007/978-3-540-73677-6_9 · Cited by 19
Lessons from oligodendrocyte biology on promoting repair in multiple sclerosis
Câmara, J., & ffrench‐Constant, C. (2007) · Journal of Neurology · doi:10.1007/s00415-007-1004-y · Cited by 20
Stem cell therapy for central nervous system demyelinating disease
Manganas, L. N., & Maletić‐Savatić, M. (2005) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-005-0050-z · Cited by 19
Oh, L. Y. S., Goodyer, C. G., Olivier, A., & Yong, V. W. (1997) · Brain Research · doi:10.1016/s0006-8993(97)00224-2 · Cited by 24
Heterogeneity of Pathogenesis in Multiple Sclerosis: Implications for Promotion of Remyelination
Soldán, M. M. P., & Rodriguez, M. (2002) · The Journal of Infectious Diseases · doi:10.1086/344283 · Cited by 18
Complement System in Central Nervous System Disorders
Shin, M. L., Rus, H., & Niculescu, F. I. (1998) · CRC Press eBooks · doi:10.1201/b14212-24 · Cited by 18
Tanshinone IIA attenuates experimental autoimmune encephalomyelitis in rats
Yan, J., Yang, X., Han, D. K., & Feng, J. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.5431 · Cited by 18
Efectos del fingolimod en el sistema nervioso central
Cruz, V. T., & Fonseca, J. (2014) · Revista de Neurología · doi:10.33588/rn.5903.2013556 · Cited by 19
Allelic variation in the Tyk2 and EGF genes as potential genetic determinants of CNS repair
Bieber, A. J., Suwansrinon, K., Kerkvliet, J. G., Zhang, W., Pease, L. R., & Rodriguez, M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906589107 · Cited by 18
Remyelination in multiple sclerosis: a challenge for therapy
Compston, A. (1997) · Multiple Sclerosis Journal · doi:10.1177/135245859700300201 · Cited by 18
Antibody-mediated Remyelination: Relevance to Multiple Sclerosis
Bieber, A. J., Asakura, K., Warrington, A. E., Kaveri, S. V., & Rodriguez, M. (2000) · Multiple Sclerosis Journal · doi:10.1177/135245850000602s01 · Cited by 17
MRI evolution of new MS lesions enhancing after different doses of gadolinium
Rovaris, M., Mastronardo, G., Gasperini, C., Prandini, F., Yousry, T. A., & Filippi, M. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1998.tb01725.x · Cited by 17
Mathisen, P. M., Yu, M., Yin, L., Johnson, J. M., Kawczak, J. A., Nishiyama, A., & Tuohy, V. K. (1999) · Journal of Autoimmunity · doi:10.1006/jaut.1999.0287 · Cited by 19
Future prospects for the management of multiple sclerosis
Compston, A. (1994) · Annals of Neurology · doi:10.1002/ana.410360736 · Cited by 17
BCAS1-positive oligodendrocytes enable efficient cortical remyelination in multiple sclerosis
Bergner, C. G., van der Meer, F., Franz, J., Vakrakou, A., Würfel, T., Nessler, S., Schäfer, L., Nau-Gietz, C., Winkler, A., Lagumersindez-Denis, N., et al. (2025) · Brain · doi:10.1093/brain/awae293 · Cited by 20
Teriflunomide Promotes Oligodendroglial 8,9-Unsaturated Sterol Accumulation and CNS Remyelination
Martin, E., Aigrot, M., Lamari, F., Bachelin, C., Lubetzki, C., Nait‐Oumesmar, B., Zalc, B., & Stankoff, B. (2021) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000001091 · Cited by 17
Cellular compensatory mechanisms in the CNS of dysmyelinated rats.
Kwiecień, J. M. (2010) · PubMed · Cited by 16
Evaluation strategy to determine reliable demyelination in the cuprizone model
Chrzanowski, U., Schmitz, C., Horn-Bochtler, A., Nack, A., & Kipp, M. (2019) · Metabolic Brain Disease · doi:10.1007/s11011-018-0375-3 · Cited by 16
Mashayekhi, F., Salehi, Z., & Jamalzadeh, H. R. (2012) · Acta Medica (Hradec Kralove Czech Republic) · doi:10.14712/18059694.2015.60 · Cited by 16
Nagasato, K., Farris, R. W., Dubois-Dalcq, M. E., & Voskuhl, R. R. (1997) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(96)00137-3 · Cited by 16
Spontaneous remyelination following prolonged inhibition of α4 integrin in chronic EAE
Piraino, P. S., Yednock, T. A., Messersmith, E. K., Pleiss, M. A., Freedman, S. B., Hammond, R. R., & Karlik, S. J. (2005) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2005.06.018 · Cited by 17
Remyelination by Endogenous Glia
Franklin, R. J. M., & Goldman, J. E. (2004) · Elsevier eBooks · doi:10.1016/b978-012439510-7/50060-7 · Cited by 17
Multiple Sclerosis: Multiple Etiologies, Multiple Genes?
Tienari, P. J. (1994) · Annals of Medicine · doi:10.3109/07853899409147901 · Cited by 15
McKay, Blakemore, & Franklin, R. J. M. (1998) · Neuropathology and Applied Neurobiology · doi:10.1046/j.1365-2990.1998.00148.x · Cited by 18
Kitzler, H. H., Wahl, H., Kuntke, P., Deoni, S., Ziemssen, T., Linn, J., & Köhler, C. (2022) · NeuroImage Clinical · doi:10.1016/j.nicl.2022.103192 · Cited by 15
“5 to 18 months after disease onset (Prineas et al., 1993).”
Cell-Based Reparative Therapies for Multiple Sclerosis
Ben‐Hur, T., Fainstein, N., & Nishri, Y. (2013) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-013-0397-5 · Cited by 17
Matejuk, A., Matejuk, S., Offner, H., & Vandenbark, A. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178314 · Cited by 14
“New lesions normally remyelinate as a result of differentiation and recruitment of oligodendrocyte progenitor cells unless interrupted by recurrent activity [4].”
Lee, J. Y., Biemond, M., & Petratos, S. (2015) · Neurodegenerative Disease Management · doi:10.2217/nmt.15.50 · Cited by 15
Wang, C., Barton, J., Kyle, K., Ly, L., Barnett, Y., Hartung, H., Reddel, S. W., Beadnall, H. N., Taha, M., Klistorner, A. I., et al. (2021) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2021-326164 · Cited by 13
Wang, C., Paling, D., Chen, L., Hatton, S. N., Lagopoulos, J., Aw, S. T., Kiernan, M. C., & Barnett, M. H. (2014) · Multiple Sclerosis Journal · doi:10.1177/1352458514556301 · Cited by 17
Transdermal histamine in multiple sclerosis, part two: a proposed theoretical basis for its use.
Gillson, G., Wright, J. V., DeLack, E., & Ballasiotes, G. (2000) · PubMed · Cited by 16
Glial Precursor Cells in the Adult Human Brain
Scolding, N. J. (1998) · The Neuroscientist · doi:10.1177/107385849800400415 · Cited by 14
TSUKAMOTO, T., Noguchi, M., Kayama, H., Watanabe, T., Asoh, T., & Yamamoto, T. (1995) · Internal Medicine · doi:10.2169/internalmedicine.34.229 · Cited by 12
Current trends in multiple sclerosis research: an update on pathogenic concepts.
Vanderlocht, J., Hellings, N., Hendriks, J. J. A., & Stinissen, P. (2006) · PubMed · Cited by 13
Cell therapy in demyelinating diseases
Rice, C. M., Halfpenny, C. A., & Scolding, N. J. (2004) · Neurotherapeutics · doi:10.1602/neurorx.1.4.415 · Cited by 13
Do Antibodies Stimulate Myelin Repair in Multiple Sclerosis?
McGavern, D. B., Asakura, K., & Rodriquez, M. (1999) · The Neuroscientist · doi:10.1177/107385849900500104 · Cited by 12
Metadata
- Authors
- Prineas, J. W., Barnard, R. O., Kwon, E. E., Sharer, L. R., & Cho, E. ‐.
- Affiliations
- East Orange VA Medical Center (US)
- Rutgers New Jersey Medical School (US)
- Corresponding author
- Prineas, J. W.
- ORCID
- Prineas, J. W.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 1993-02
- Volume
- 33
- Issue
- 2
- Pages
- 137-151
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2024751716
- Cited by
- 574
- References
- 46
- Citations by year
- 2026: 8 · 2025: 9 · 2024: 7 · 2023: 9 · 2022: 10 · 2021: 13 · 2020: 14 · 2019: 19 · 2018: 14 · 2017: 12 · 2016: 10 · 2015: 14 · 2014: 18 · 2013: 13 · 2012: 16
- FWCI
- 15.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Annals of Neurology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Life Sciences › Neuroscience › Developmental Neuroscience › Neurogenesis and neuroplasticity mechanisms
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- multiple sclerosis, remyelination, demyelination, oligodendrocytes, myelin destruction, disease duration, early-onset multiple sclerosis
- MeSH terms
- Adolescent, Adult, Aged, Axons, Female, Humans, Male, Middle Aged, Multiple Sclerosis, Myelin Sheath, Nerve Regeneration, Oligodendroglia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.